Intermediate for Ibrutinib. Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.
Product Name: (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
CAS Number: 1022150-11-3
Molecular Weight:  486.5724
Molecular Formula:  C27H30N6O3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.